PatientsVille.com Logo

Osteoporosis and Adcal

PatientsVille

Osteoporosis Symptoms and Causes

Osteoporosis is a disease that thins and weakens the bones. Your bones become fragile and break easily, especially the bones in the hip, spine, and wrist. In the United States, millions of people either already have Osteoporosis or are at high risk due to low bone mass.

Anyone can develop Osteoporosis, but it is more common in older women. Risk factors include

  • Getting older
  • Being small and thin
  • Having a family history of Osteoporosis
  • Taking certain medicines
  • Being a white or Asian woman
  • Having low bone density

Osteoporosis is a silent disease. You might not know you have it until you break a bone. A bone mineral density test is the best way to check your bone health.

To keep bones strong, eat a diet rich in calcium and vitamin D, exercise, and do not smoke. If needed, medicines can also help. It is also important to try to avoid falling down. Falls are the number one cause of fractures in older adults.

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

Check out the latest treatments for osteoporosis

➢ osteoporosis treatment research studies

➢ Adcal clinical trials, surveys and public health registries

Find Drug Side Effect reports



Adcal Side Effects

Cough (7)
Nail Disorder (7)
Vasculitis (6)
Platelet Count Decreased (5)
Skin Warm (5)
Rash Erythematous (5)
Pallor (5)
Dyspnoea (4)
Neutropenic Sepsis (4)
Neutrophil Count Decreased (4)
Escherichia Urinary Tract Infection (3)
Escherichia Sepsis (3)
Death (3)
Haemoglobin Decreased (3)
Pancytopenia (3)
Onychomycosis (3)
Pyrexia (3)
Pneumonia (3)
Cardiac Failure (2)
Condition Aggravated (2)
Blood Count Abnormal (2)
Asthma (2)
Erythema (2)
Chorea (2)
Pruritus (2)
Fall (2)
Swelling Face (2)
Hyperkalaemia (2)
Oesophageal Carcinoma (2)
Purpura (2)
Infection (2)
Malaise (2)
White Blood Cell Count Decreased (1)
Idiopathic Thrombocytopenic Purpura (1)
Wheezing (1)
Hypoglycaemia (1)
Trigeminal Nerve Disorder (1)
Subarachnoid Haemorrhage (1)
Infusion Related Reaction (1)
Unresponsive To Stimuli (1)
Urticaria (1)
Sense Of Oppression (1)
Subdural Haematoma (1)
Syncope (1)
Tachypnoea (1)
Injection Site Urticaria (1)
Sepsis (1)
Febrile Neutropenia (1)
Scleritis (1)
Toxicity To Various Agents (1)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I also have had pains in my sides and my rib area since taking a higher dose of Adcal. I also noticed I now feel nauseas and have more joint pain. I really didn't expect this. I have been on Adcal for three years now and still my calcium and vitamin

I have been taking adcal dissolve 3000mg for several months now. since taking this i have had severe constipation and griping wind along with flatulence. should i go back to my gp or can you advise me to help my digestive system. it is becoming embar

Joint pain

Since I have been taking Adcal-D3 I noticed a dull pain on my left side towards the back at the level of the kidneys. I wonder if anyone else had the same problem.

What will be the effect of Adcal if you take on a long term?

All this scares me. my doctor insists I get the injection. I have osteoporosis and she says it's a choice of falling and breaking a hip or the reclast. I can't take boniva or other oral meds like it because I've got gerd and they upset my chest.

Dear Chris, My mother was diagnosed with osteoporosis a few months ago. She has been taking Fosavance since October/November 2009. I have noticed her rubbing her legs, arms and joints (shoulders, knees) frequently over the past few weeks and compl

Dear friends, I'm a 51 year old woman who has had an early menopause, at the age of 32. I'm at the beginning of osteoporosis and my doctor insists on me taking the annual infusion of Alcasta medicine. I would be grateful to you if I could have an o

Fosavance is a terrible drug and should be taken off the market, my bone density results were a bit worse after being on Fosavance for 3 years. Is there no other drug that the world can come up with because anyone with osteoporosis can tell you how y

Have others had their doctors do a bone mineral densiity test? I hsve osteopenia in some places and osteoporosis in others - and no other risk factors. It's all due to the use of the AEDs. I have checked the research. If you are on this long term

Having suffered 3 dvt's, 1 pulmonary embolism, 1 stroke and 2 tis's, I was given Fragmin. I previously had been taking warfarin for about 20 yrs, this ceased to work. I am now told that I have Osteoporosis... I seem to remember along the way that

Hi, I Don't think I have Osteonecrois even though me jaw started hurting about 6 month's ago. I have been taking Actonel for 16 years now because. because of my Osteoporosis. I didn't have this infliction until I completed three trips to Chernoby

I have been advised to have an infusion ,as I cannot tolerate zolendronate orally. I re-act to a lot of medicines adversely and am worried. My osteoporosis has deteriorated 8 and a half pre cent in the last three years. Advice please.

I have been on Risedronate since 2008 because I have osteoporosis and now I am diagnosed with Immuno thrombocytopeniaI am 60 years old

I have been taking epilim for bipolar disorder for 15 years now,it has help keep me relatively stable.However i have just been diagnosed with osteopenia, the first stages of osteoporosis.I am only 46 years old.I have just started an increased dose of

Osteoporosis Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown † Osteoporosis Among Men Treated With Androgen Deprivation for Prostate Cancer
Conditions: Prostate Cancer;   Androgen Deprivation Therapy;   Osteoporosis
Intervention: Procedure: blood sampling, DXA-scan, bone scintigraphy
Outcome Measure: Osteoporosis, either T-score < -2,5 or Osteoporosis fracture
2 Recruiting Evaluation of an Osteoporosis Prevention Strategy in Women With Osteoporotic Fracture of the Upper Limb
Condition: Osteoporosis With Current Fragility Fracture
Intervention: Behavioral: Osteoporosis prevention program
Outcome Measures: Proportion of women in the 2 groups who initiated a management of Osteoporosis at 6 months (BMD or Osteoporosis treatment prescription).;   Proportion of women in the two groups who performed BMD at 6 months;   Proportion of women in the two groups with an increased perception of fracture risk.;   Proportion of women in the two groups who changed their behaviour in order to prevent future fractures: regular practice of physical activity, dairy products consumption and calcium and vitamin D supplementation.;   Proportion of women who improved their knowledge about Osteoporosis
3 Unknown † Osteoporosis Coordinator for Low Volume Community Hospitals
Conditions: Osteoporosis;   Fragility Fractures
Interventions: Behavioral: centralized Osteoporosis coordinator;   Behavioral: fall prevention
Outcome Measures: proportion of patients from the intervention group as compared to the control group that had "appropriate management" based on a composite of undergoing a BMD test and starting therapy within 6 months of fracture.;   Osteoporosis knowledge, perceived susceptibility, self-efficacy, preventive behaviors;   participants' experience and perceptions of future fracture risk; their understanding of the educational materials and acceptance of recommended treatment plans.
4 Recruiting Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women
Condition: Adult Idiopathic Generalized Osteoporosis
Interventions: Drug: Teriparatide;   Drug: Saline Placebo
Outcome Measure: Change in lumbar spine bone mineral density (LS-BMD)
5 Recruiting Study on the microRNA Expression Level in Postmenopausal Osteoporosis
Condition: Postmenopausal Osteoporosis
Intervention: Other: Osteoporosis
Outcome Measure: microRNA expression lever in the Peripheral Blood
6 Recruiting Age Dependend Diagnostic Thresholds for Osteoporosis Bindex Ultrasonometer
Condition: Osteoporosis
Intervention:
Outcome Measure: Thresholds for Bindex in Osteoporosis Diagnostics
7 Unknown † Multi-joint Coordination Underlies Upright Balance Control in Elderly With Osteoporosis
Condition: Osteoporosis
Intervention:
Outcome Measure:
8 Recruiting Osteoporosis in RETT Syndrome
Condition: RETT Syndrome With Proven MECP2 Mutation
Intervention: Other: biological markers and evaluation of the mineral density at the lumber spine using DEXA
Outcome Measures: Osteoporosis in RETT patients;   Biological Mechanisms of Osteoporosis
9 Unknown † A Interventional Study of Geriatric Frailty, Osteoporosis, and Depression
Conditions: Frailty;   Osteoporosis;   Depression
Intervention:
Outcome Measures: Including physical health, mental health, social functioning, quality of life, daily functioning, and health care resource utilizations. Feasibility analysis is applied to assess the possibility for large scale disseminations of the proposed project.;   The results of the proposed study will help shaping the geriatric healthcare policy toward the goal of "active aging" in Taiwanese community-dwelling elders.
10 Recruiting Gaining Optimal Osteoporosis Assessments in Long-Term Care (GOAL)
Condition: Osteoporosis
Intervention: Other: Knowledge Translation Education Sessions
Outcome Measures: Difference in the percentage of residents appropriately prescribed an Osteoporosis medication before and after the intervention.;   Difference in the percentage of residents prescribed Vitamin D (equivalent to ≥800 IU/day) before and after the intervention.
11 Not yet recruiting Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday
Condition: Osteoporosis
Intervention: Other: Questionnaires about compliance and persistence with bisphosphonates treatment
Outcome Measure: Compliance and persistence to Osteoporosis drug therapy
12 Recruiting Weekly vs Daily Teriparatide Therapy in Severe Postmenopausal Osteoporosis
Condition: Osteoporosis
Intervention: Drug: Teriparatide
Outcome Measures: BMD at Hip and lumber spine;   Reduction in fracture risk
13 Recruiting Improved Screening for Osteoporosis
Condition: Osteoporosis
Intervention:
Outcome Measure: Number of patients screened at risk for Osteoporosis
14 Unknown † Vitamin K as Additive Treatment in Osteoporosis
Condition: Post-Menopausal Osteoporosis
Interventions: Drug: Phylloquinone;   Drug: Menaquinone (MK4);   Drug: placebo
Outcome Measures: Primary outcome measures- Changes in BMD at the Lumber spine, hip, fore-arm at 18 months.;   Secondary outcome measure- Bone Turnover as assessed by the biochemical markers (serum CTX, P1NP, BALP, carboxylated and undercarboxylated osteocalcin (OC), OPG). These markers will be measured at the same time point during each clinic visit.
15 Not yet recruiting Growth Hormone for Osteoporosis Pseudoglioma Syndrome
Condition: Osteoporosis Pseudoglioma Syndrome
Intervention: Biological: Human recombinant growth hormone
Outcome Measures: Bone quality by pQCT;   Body fat percent
16 Recruiting Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis
Condition: Osteoporosis
Intervention: Drug: Teriparatide
Outcome Measure: Change in cortical thickness at the radius and tibia as measured by high-resolution quantitative computer tomography (HR-pQCT)
17 Not yet recruiting C-STOP Fracture Trial
Condition: Osteoporosis
Interventions: Other: case management;   Other: Multifaceted quality improvement intervention
Outcome Measure: Proportion of untreated patients newly starting prescription Osteoporosis treatment with a bisphosphonate after their fracture
18 Unknown † Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids
Condition: Osteoporosis
Intervention: Device: Dual energy X-ray absorptiometry
Outcome Measure: Diagnosis of Osteoporosis
19 Not yet recruiting Longitudinal Study of Primary Osteoporosis in Shanghai Postmenopausal Women
Condition: Primary Osteoporosis
Intervention:
Outcome Measures: Bone Mineral Density;   SF-36;   international Osteoporosis foundation ONE-MINUTE Osteoporosis RISK TEST;   Markers of bone metabolism test;   EQ-5D;   Hepatic-renal function test;   thyroid stimulating hormone level test
20 Recruiting Phase 2a Study on Intravenous Infusion of Autologous Osteoblastic Cells in Severe Osteoporosis
Condition: Severe Osteoporosis
Intervention: Drug: PREOB® Intravenous Infusion
Outcome Measures: Cell biodistribution after intravenous infusion as assessed by SPECT/CT scan;   Potential occurrence of any AE or SAE, related to the product, using patient open non-directive questionnaire, physical examination and laboratory measurements;   Pain measured by the Visual Analogue Scale;   Well-being score using SF-36 questionnaire;   Occurrence of new vertebral fractures as assessed by X-ray;   Bone mineral density evolution as assessed by Dual-energy X-ray absorptiometry (DEXA);   Measurement of bone formation and resorption markers